09R.F Skye Bioscience, Inc.
- Market cap
- EUR 846K
- P/E
- -
- P/B
- 1.92x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 09R.F undervalued?
Graham numberThe Graham number of Skye Bioscience, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Skye Bioscience, Inc. fundamental analysis
No fundamental analysis for Skye Bioscience, Inc. yet.
Skye Bioscience, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues wi…
Full company profileSkye Bioscience, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Skye Bioscience, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.85M | -12.1M | -13.7M | -36.4M | -58.2M | -41.0M |
| EBITDA | - | -18.7M | -36.6M | -25.3M | -55.2M | -45.9M |
| Net Income | -8.52M | -19.5M | -37.6M | -26.6M | -55.9M | -46.6M |
| EPS | -4.47 | -43 | -24 | -6.86 | -13 | -11 |
| Balance Sheet | ||||||
| Total Assets | 9.86M | 9.11M | 11.9M | 72.8M | 28.3M | 11.0M |
| Total Liabilities | 3.99M | 12.1M | 14.1M | 4.61M | 8.29M | 11.5M |
| Shareholders' Equity | 5.86M | -3.01M | -2.13M | 68.2M | 20.0M | -497K |
| Cash & Short-term Investments | 8.98M | 1.24M | 1.26M | 68.4M | 5.88M | 8.07M |
| Cash Flow | ||||||
| Operating Cash Flow | -6.47M | -12.7M | -14.0M | -25.2M | -43.1M | -31.4M |
| Capital Expenditure | 90.9K | 28.1K | 12.6K | 1.60M | 6.31K | 0.00 |
| Free Cash Flow | -6.57M | -12.8M | -14.0M | -26.8M | -43.1M | -31.4M |
| Ratios | ||||||
| ROE | -145.3% | - | - | -39.0% | -279.3% | - |
| ROA | -86.5% | -213.8% | -315.3% | -36.5% | -197.5% | -422.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Skye Bioscience, Inc. dividends
Skye Bioscience, Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:8 on Aug 24, 2026.
Who owns Skye Bioscience, Inc.
- Insiders 4.24%
- Institutions 44.50%
- Public & others 51.27%
- Shares outstanding 4.43M
- Free float 2.76M
Skye Bioscience, Inc. company profile
- Company name
- Skye Bioscience, Inc.
- Ticker
- 09R.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 11250 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 410 0266
- Website
- skyebioscience.com
About Skye Bioscience, Inc.
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Skye Bioscience, Inc. management
5- Mr. Punit S. Dhillon B.A.President, CEO & Director · born 1980
- Mr. Tu Diep M.Sc.Chief Operating Officer · born 1981
- Mr. John P. Sharp CPACFO and Principal Financial & Accounting Officer · born 1965
- Dr. Christopher G. Twitty Ph.D.Chief Scientific Officer · born 1972
- Dr. Puneet S. Arora FACE, M.D., M.S.Chief Medical Officer · born 1972